当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
Verquvo
申请企业
MERCK SHARP AND DOHME CORP
承诺描述
A worldwide descriptive study that collects prospective and retrospective data in women exposed to vericiguat during pregnancy to assess risk to the pregnancy and maternal complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant. Infant outcomes will be assessed through at least the first year of life. The study will collect information for a minimum of 10 years. Results will be analyzed and reported descriptively. Data collected retrospectively will be analyzed separately and reported with the interim and final study reports.